![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-desktop-header-01gif-33629.gif)
![Renejix CDMO Partner for Small Molecule Oral Dosage Forms](https://www.pharmacompass.com/image/flap/renejix-w35-mob-header-01gif-17728.gif)
API Suppliers
US DMFs Filed
CEP/COS Certifications
JDMFs Filed
EU WC
Listed Suppliers
USA (Orange Book)
Europe
Canada
Australia
South Africa
Uploaded Dossiers
U.S. Medicaid
Annual Reports
0
1. 4-ethylamino-5,6-dihydro-6-methyl-7,7-dioxide-4h-thieno(2,3-b)thiopyran-2-sulfonamide
2. 5,6-dihydro-4-ethylamino-6-methyl-4h-thieno(2,3-b)thiopyran-2-sulfonamide-7,7-dioxide
3. Dorzolamide
4. Dorzolamide Chibret
5. Dorzolamide, (trans)-isomer
6. L 671152
7. L-671,152
8. Mk 507
9. Mk-507
10. Trusopt
1. 130693-82-2
2. Dorzolamide Hcl
3. Trusopt
4. Dorzolomide Hydrochloride
5. Cosopt
6. Dorzolamide (hydrochloride)
7. Mk-507
8. Dorzolomide Hcl
9. (4s,6s)-4-(ethylamino)-6-methyl-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide 7,7-dioxide Hydrochloride
10. Dorzolamide (as Hydrochloride)
11. Qzo5366ew7
12. Trusopt (tn)
13. Dsstox_cid_25530
14. Dsstox_rid_80933
15. Dsstox_gsid_45530
16. (4s,6s)-4-(ethylamino)-5,6-dihydro-6-methyl-4h-thieno(2,3-b)thiopyran-2-sulfonamide 7,7-dioxide, Monohydrochloride
17. Chebi:4703
18. (4s,6s)-4-(ethylamino)-6-methyl-7,7-dioxo-5,6-dihydro-4h-thieno[2,3-b]thiopyran-2-sulfonamide;hydrochloride
19. 4h-thieno(2,3-b)thiopyran-2-sulfonamide, 4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide, Monohydrochloride, (4s-trans)-
20. Unii-qzo5366ew7
21. Sr-05000001449
22. Dorzolamide Hydrochloride [usan]
23. L 671152
24. L-671,152
25. Dorzolamide Hcl Salt
26. Dorzolamide Hydrochloride [usan:usp]
27. Mk507 Hydrochloride
28. Mk 0507
29. Mk-0507
30. L671152 Hydrochloride
31. Ncgc00016977-01
32. Cas-130693-82-2
33. Schembl41152
34. Mls002154162
35. Chembl1201162
36. Dtxsid1045530
37. Dorzolamide Hydrochloride- Bio-x
38. Hy-b0109a
39. Hms1571o14
40. Ex-a3987
41. Tox21_110720
42. Mfcd00884659
43. S1375
44. Dorzolamide Hydrochloride [mi]
45. Akos005146235
46. Akos015895951
47. Dorzolamide Hydrochloride (jp17/usp)
48. Tox21_110720_1
49. Ac-5244
50. Ccg-221116
51. Cs-1858
52. Dorzolamide Hydrochloride [jan]
53. Ks-1348
54. Dorzolamide Hydrochloride [mart.]
55. Dorzolamide Hydrochloride [vandf]
56. Ncgc00179244-03
57. Bd164381
58. Dorzolamide Hydrochloride [usp-rs]
59. Dorzolamide Hydrochloride [who-dd]
60. Smr001233461
61. Mk-507 (l-671152) Hcl
62. D4189
63. Dorzolamide Hydrochloride, Trans-(-)-
64. C72221
65. D00653
66. Dorzolamide Hydrochloride [orange Book]
67. Dorzolamide Hydrochloride [usp Impurity]
68. Cosopt Component Dorzolamide Hydrochloride
69. Dorzolamide Hydrochloride [usp Monograph]
70. 279d961
71. Dorzolamide Hydrochloride Component Of Cosopt
72. L-671152
73. Sr-05000001449-3
74. Q27106441
75. Dorzolamide Hydrochloride, European Pharmacopoeia (ep) Reference Standard
76. Dorzolamide For System Suitability, European Pharmacopoeia (ep) Reference Standard
77. Dorzolamide Hydrochloride, United States Pharmacopeia (usp) Reference Standard
78. (4s,6s)-4-(ethylamino)-5,6-dihydro-6-methyl-, 7,7-dioxide 4h-thieno[2,3-b]thiopyran-2-sulfonamide Hydrochloride
79. 122028-16-4
80. 4h-thieno(2,3-b)thiopyran-2-sulfonamide, 5,6-dihydro-4-(ethylamino)-6-methyl-, 7,7-dioxide, Monohydrochloride, (4s,6s)-
Molecular Weight | 360.9 g/mol |
---|---|
Molecular Formula | C10H17ClN2O4S3 |
Hydrogen Bond Donor Count | 3 |
Hydrogen Bond Acceptor Count | 7 |
Rotatable Bond Count | 3 |
Exact Mass | 360.0038982 g/mol |
Monoisotopic Mass | 360.0038982 g/mol |
Topological Polar Surface Area | 151 Ų |
Heavy Atom Count | 20 |
Formal Charge | 0 |
Complexity | 534 |
Isotope Atom Count | 0 |
Defined Atom Stereocenter Count | 2 |
Undefined Atom Stereocenter Count | 0 |
Defined Bond Stereocenter Count | 0 |
Undefined Bond Stereocenter Count | 0 |
Covalently Bonded Unit Count | 2 |
1 of 4 | |
---|---|
Drug Name | Cosopt |
PubMed Health | Dorzolamide/Timolol (Into the eye) |
Drug Classes | Antiglaucoma, Beta-Adrenergic Blocker/Carbonic Anhydrase Inhibitor Combination |
Active Ingredient | Dorzolamide hydrochloride; timolol maleate |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base; eq 2% base |
Market Status | Prescription |
Company | Oak Pharms Akorn |
2 of 4 | |
---|---|
Drug Name | Dorzolamide hydrochloride |
Drug Label | Dorzolamide Hydrochloride Ophthalmic Solution USP, 2% is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.Dorzolamide hydrochloride, USP is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]th... |
Active Ingredient | Dorzolamide hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 2% base |
Market Status | Prescription |
Company | Watson Labs; Zach Systems; Teva Pharms; Hi Tech Pharma; Bausch And Lomb; Alcon Pharms; Luitpold; Sandoz |
3 of 4 | |
---|---|
Drug Name | Cosopt |
PubMed Health | Dorzolamide/Timolol (Into the eye) |
Drug Classes | Antiglaucoma, Beta-Adrenergic Blocker/Carbonic Anhydrase Inhibitor Combination |
Active Ingredient | Dorzolamide hydrochloride; timolol maleate |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 0.5% base; eq 2% base |
Market Status | Prescription |
Company | Oak Pharms Akorn |
4 of 4 | |
---|---|
Drug Name | Dorzolamide hydrochloride |
Drug Label | Dorzolamide Hydrochloride Ophthalmic Solution USP, 2% is a carbonic anhydrase inhibitor formulated for topical ophthalmic use.Dorzolamide hydrochloride, USP is described chemically as: (4S-trans)-4-(ethylamino)-5,6-dihydro-6-methyl-4H-thieno[2,3-b]th... |
Active Ingredient | Dorzolamide hydrochloride |
Dosage Form | Solution/drops |
Route | Ophthalmic |
Strength | eq 2% base |
Market Status | Prescription |
Company | Watson Labs; Zach Systems; Teva Pharms; Hi Tech Pharma; Bausch And Lomb; Alcon Pharms; Luitpold; Sandoz |
Antihypertensive Agents
Drugs used in the treatment of acute or chronic vascular HYPERTENSION regardless of pharmacological mechanism. Among the antihypertensive agents are DIURETICS; (especially DIURETICS, THIAZIDE); ADRENERGIC BETA-ANTAGONISTS; ADRENERGIC ALPHA-ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; CALCIUM CHANNEL BLOCKERS; GANGLIONIC BLOCKERS; and VASODILATOR AGENTS. (See all compounds classified as Antihypertensive Agents.)
Carbonic Anhydrase Inhibitors
A class of compounds that reduces the secretion of H+ ions by the proximal kidney tubule through inhibition of CARBONIC ANHYDRASES. (See all compounds classified as Carbonic Anhydrase Inhibitors.)